Publications by authors named "R Tachdjian"
The utility of shared decision making in the management of hereditary angioedema.
Allergy Asthma Proc
November 2024
Hereditary angioedema (HAE) is a complex disorder with a wide array of treatment options. Shared decision-making (SDM) should be used to ensure that patients are choosing their best treatment option. The goal was to develop and psychometrically test a brief instrument for assessing the patient's perspective of the SDM process during his or her clinical encounters with an HAE specialist/allergist.
View Article and Find Full Text PDFLong-term prophylaxis (LTP) has been shown to reduce the frequency of hereditary angioedema (HAE) attacks; however, attacks occurring in patients receiving LTP have not been well characterized. The objective of this systematic review was to evaluate the proportion of type I/II HAE (HAE-C1INH) patients who experience attacks while receiving LTP, the characteristics of these attacks, and associated on-demand therapy use. A systematic search was conducted in PubMed to identify studies reporting LTP use with plasma-derived C1 inhibitor (pdC1INH), lanadelumab, berotralstat, androgens, or antifibrinolytics in patients with HAE-C1INH.
View Article and Find Full Text PDFArticle Synopsis
- * A survey of 144 HAE patients showed that those receiving lanadelumab experienced fewer attacks and reported a better quality of life compared to those on other long-term therapies.
- * The findings indicate that patients treated with lanadelumab not only had lower attack frequency but also faced a lower symptomatic impact, suggesting it may be a more effective treatment option.
Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.
Ann Allergy Asthma Immunol
December 2024
Background: Lanadelumab was well tolerated and effective in preventing hereditary angioedema (HAE) attacks in the phase 3, double-blind, placebo-controlled Hereditary angioEdema Long-term Prophylaxis (HELP) study and subsequent HELP open-label extension (OLE) study (NCT02741596).
Objective: To evaluate outcomes from HELP OLE for adolescent patients aged 12 to 17 years.
Methods: The HELP OLE study comprised patients who completed the HELP study (rollovers) and new eligible (lanadelumab-naive) patients.